Find a Clinical Trial

Showing 41 - 50 of 179 Trials

  • The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER)

    Principal Investigator:

    Catherine S Spina, MD, PhD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT07097142

    Population:

    Adult

    Phase:

    III
    This study is being done to answer the following question: Is radiation given at higher doses over a shorter timeframe plus chemotherapy as good as the usual radiation and chemotherapy at preventing your bladder cancer from getting worse and avoiding bladder removal surgery? We are doing this study because we want to find out if this approach is the same as the usual approach for your bladder cancer. The usual approach for patients who are not in a study is treatment with surgery, radiation, or chemotherapy approved by the Food and Drug Administration (FDA). Sometimes, combinations of these...

  • Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer

    Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06513962

    Population:

    Pediatrics/Adult

    Phase:

    III
    Reproductive health outcomes, including the possibility of infertility from cancer treatment, are a major source of distress for adolescent and young adult (AYA) patients from diagnosis through survivorship. The overarching objective of this study is to investigate the impact of the Gonadotropin Releasing Hormone agonist (GnRHa) triptorelin, as a randomized intervention, on the ovarian reserve of newly diagnosed AYA cancer patients (exclusive of breast cancer) treated with alkylating agent chemotherapy. This trial is supported by the NCI Community Oncology Research Program (NCORP), led by the...

  • A Multipart, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ELA026 in Participants with Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

    Principal Investigator:

    Seda S Tolu, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05416307

    Population:

    Adult

    Phase:

    II/III
    This study is testing an investigational drug called ELA026 in people who have a rare and serious immune condition called secondary hemophagocytic lymphohistiocytosis (sHLH). Investigational means that it is not approved by the United States Food and Drug Administration (FDA). sHLH causes the immune system to become overactive, leading to inflammation and damage to organs. ELA026 is designed to target specific immune cells that may contribute to the inflammation seen in sHLH. The study will also use dexamethasone, an FDA-approved steroid commonly used to help control inflammation. In this...

  • An International, Seamless Phase II/III Responsive Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (GBM AGILE)

    Principal Investigator:

    Andrew B. Lassman, MD, FAAN, FASCO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT03970447

    Population:

    Adult

    Phase:

    II/III
    The purpose of this study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. Investigational means that these are new treatments sometimes called “study drugs” and are not approved by the Food and Drug Administration (FDA) to be used for your type of cancer. The investigational treatments in this study have been previously tested in people. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Do you...

  • A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

    Principal Investigator:

    Joseph G. Jurcic, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04910685

    Population:

    Adult

    Phase:

    II/III
    You are being asked to participate in this study because you have indolent SM (ISM) or because you have Monoclonal mast cell activation syndrome (mMCAS). Currently, there are no available targeted therapies for patients with ISM or mMCAS. The study will test the drug BLU-263. BLU-263 is a new study drug that is being developed for treating people like you, with ISM and/or mMCAS. BLU-263 is not yet approved for treating ISM and/or mMCAS by the Food and Drug Administration (FDA). BLU-263 is the first study drug in a group of drugs that prevents a specific DNA change called KIT D816V. The goal...

  • AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

    Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05691478

    Population:

    Pediatrics/Adult

    Phase:

    II/III
    This Phase III trial investigates if the incorporation of immunotherapy will improve progression-free survival (PFS) and maintain overall survival (OS) while simultaneously minimizing long-term morbidity and treatment-related mortality by reducing exposure to radiotherapy and high cumulative chemotherapy doses. The study will enroll patients ages 5 to 60 years with newly diagnosed early-stage cHL and will investigate the targeted CD30-antibody drug conjugate, Brentuximab Vedotin (Bv), with PD-1 blockade (nivolumab) compared with a standard chemotherapy regimen, with or without RT Are you...

  • A Phase II trial of avutometinib in combination with defactinib in metastatic diffuse gastric cancer

    Principal Investigator:

    Ryan H. Moy, MD, PhD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06487221

    Population:

    Adult

    Phase:

    II
    There are two main types of stomach cancer based on the appearance under the microscope: intestinal-type and diffuse-type. Some stomach cancers also have a mix of intestinal-type and diffuse-type (mixed type). You are being invited to take part in this research study because you have been diagnosed with stomach cancer that has spread to other parts of the body and/or cannot be surgically removed, has diffuse-type or mixed-type cells or has gene alterations that are associated with diffuse-type stomach cancers (such as mutations in the genes CDH1 or RHOA), and you have already been treated...

  • A RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FOR LARGE B-CELL LYMPHOMA (ALPHA3)

    Principal Investigator:

    Ran Reshef, MD, MSc

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06500273

    Population:

    Adult

    Phase:

    II
    The study aims to see if CAR T cells made from healthy donors are an effective study treatment to prevent relapse in participants who have lymphoma DNA detected in their blood by an investigational test. The study evaluates two investigational products – ALLO- 647, an antibody (protein) that may help prepare the body for receiving CAR T cells from healthy donors, and a CAR T cell study treatment called cemacabtagene ansegedleucel or cema-cel. Both ALLO-647 and cema-cel are investigational drugs and therefore not approved by the Food and Drug Administration (FDA). For reference, CAR T...

  • A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participants with cancer harboring BRAF alterations

    Principal Investigator:

    Mary R. Welch, MD, MS

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05503797

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to test the safety of Plixorafenib and how well your disease responds to the study treatment. Plixorafenib has not been approved by the Food and Drug Administration (FDA). Your study treatment may or may not include a drug called Cobicistat. Cobicistat is approved by FDA but is not FDA approved in combination with plixorafenib. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Ability to swallow and retain medication - Must not have known sensitivity to Plixorafenib and Cobicistat

  • AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

    Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04322318

    Population:

    Pediatrics/Adult

    Phase:

    II
    This is a Phase 2 study of patients for the treatment of patients with high risk Wilms tumors (including those with diffuse anaplastic Wilms tumor- DAWT) and those who have relapsed favorable histology Wilms tumor (FHWT). The main goal of the study is to find out whether treatment with chemotherapy consisting of vincristine/irinotecan; cyclophosphamide/carboplatin/etoposide; and vincristine/doxorubicin/cyclophosphamide) improves the survival of patients with newly diagnosed Stage 4 diffuse anaplastic Wilms tumor (DAWT) or Standard-Risk relapsed favorable histology Wilms tumor (SRrFHWT) as...

Pages

Back to top